Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing

About

The Gates Foundation and LifeArc invite innovators to submit proposals for developing low-cost monoclonal antibody manufacturing solutions, aiming to achieve a final drug substance cost of $10 per gram, with funding opportunities available for both proof-of-concept and operationalization projects, fostering collaboration and innovation in the biopharmaceutical industry.

Benefits

• Potential funding of up to $750,000 USD for Option A projects
• Grant term of up to 18 months for successful proposals
• Opportunity to develop innovative bioprocessing approaches for mAb production
• Access to a collaborative network of experts in the field

Eligibility Criteria

• Open to nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions
• Encourages projects led by women or in collaboration with women-led organizations
• Applications from institutions based in low- and middle-income countries are particularly encouraged
• Must apply through a legally recognized corporate entity